Meta Biomed Co. Ltd
Meta Biomed Co., Ltd. engages in the research and development, production, and marketing of dental and surgical materials in South Korea and internationally. The company's dental products include endodontics, endodontic materials, restorative materials, and bone graft materials. It also offers suture products comprising multifilament and monofilament products, as well as orthopedics; bone product… Read more
Meta Biomed Co. Ltd (059210) - Total Liabilities
Latest total liabilities as of September 2025: ₩58.87 Billion KRW
Based on the latest financial reports, Meta Biomed Co. Ltd (059210) has total liabilities worth ₩58.87 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Meta Biomed Co. Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Meta Biomed Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Meta Biomed Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Meta Biomed Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Reach Subsea
OL:REACH
|
Norway | Nkr2.38 Billion |
|
Ellaktor S.A
AT:ELLAKTOR
|
Greece | €1.13 Billion |
|
Cross Timbers Royalty Trust
NYSE:CRT
|
USA | $1.49 Million |
|
Lanvin Group Holdings Limited
NYSE:LANV
|
USA | $693.10 Million |
|
A W FOOD SERVICES OF CANADA INC
TO:AW
|
Canada | CA$1.02 Billion |
|
MARX Biotech Co., Ltd.
TWO:7731
|
Taiwan | NT$519.21 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Meta Biomed Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Meta Biomed Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Meta Biomed Co. Ltd (2011–2024)
The table below shows the annual total liabilities of Meta Biomed Co. Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩83.96 Billion | +46.11% |
| 2023-12-31 | ₩57.46 Billion | -4.99% |
| 2022-12-31 | ₩60.48 Billion | +34.99% |
| 2021-12-31 | ₩44.80 Billion | -25.17% |
| 2020-12-31 | ₩59.88 Billion | +19.70% |
| 2019-12-31 | ₩50.02 Billion | +4.82% |
| 2018-12-31 | ₩47.72 Billion | -35.21% |
| 2017-12-31 | ₩73.65 Billion | +7.54% |
| 2016-12-31 | ₩68.49 Billion | +8.86% |
| 2015-12-31 | ₩62.91 Billion | -11.21% |
| 2014-12-31 | ₩70.85 Billion | -1.93% |
| 2013-12-31 | ₩72.25 Billion | +15.52% |
| 2012-12-31 | ₩62.54 Billion | +321.41% |
| 2011-12-31 | ₩14.84 Billion | -- |